实用医学杂志 ›› 2021, Vol. 37 ›› Issue (13): 1737-1741.doi: 10.3969/j.issn.1006⁃5725.2021.13.019

• 药物与临床 • 上一篇    下一篇

氯吡格雷联合阿司匹林精准用药与脑卒中患者短期预后的关系

王嘉晶1,2, 况杰2, 涂江龙3, 彭晨2, 陈积标2, 殷淑娟2, 张晓林2 ,易应萍1,2    

  1. 南昌大学第二附属医院 1 信息处,3 神经内科(南昌 330006);2 南昌大学公共卫生学院,江西省预防医学 重点实验室(南昌 330006)

  • 出版日期:2021-07-10 发布日期:2021-07-10
  • 通讯作者: 易应萍 E⁃mail:yyp66@126.com 王嘉晶、况杰为共同第一作者
  • 基金资助:

    国家重点研发计划(编号:2018YFC1312902);国家 自然科学基金(编号:81960609);江西省重点研发计划(编号: 20181ACH80004 

Relationship between precision medication of clopidogrel combined with aspirin and short⁃term prognosis in patients with acute ischemic stroke

WANG Jiajing,KUANG Jie,TU Jianglong,PENG Chen,CHEN Jib⁃ iao,YIN Shujuan,ZHANG Xiaolin,YI Yingping.    

  1. Information Department,the Second Affiliated Hospital of Nan⁃ chang University,Nanchang 330006,China;Jiangxi Provincial Key Laboratory of Preventive Medicine,School of Public Health,Nanchang University,Nanchang 330006,China 

  • Online:2021-07-10 Published:2021-07-10
  • Contact: YI Yingping E⁃mail:yyp66@126.com

摘要:

目的 探索精准抗血小板用药对急性缺血性脑卒中(AIS)患者 90 d 预后和安全性的影响。 方法 在江西省14家医院招募AIS患者,对研究组患者开展精准抗血小板用药,对照组按照临床指南常规 用药。在第90天随访记录复发、mRS评分和出血事件,进行组间比较。结果 研究共招募了1 472例患者,随 访成功1 370例。研究组中存在氯吡格雷抵抗和阿司匹林抵抗的患者各占61%(428/705)和9.4%(66/705)。 研究组患者的复发率为4.1%,对照组为4.5%(P = 0.75)。研究组预后不良发生率为17.7%,对照组为23.6% (P = 0.007)。研究组的出血事件发生率为2.4%,对照组为2.8%(P = 0.67)。结论 精准抗血小板用药治疗能 有效改善AIS患者的短期预后,同时对安全性没有显著影响,可以为脑卒中的临床精准治疗提供循证依据。

关键词:

急性缺血性脑卒中, CYP2C19基因, 11?dhTxB2, 精准用药, 随机对照试验

Abstract:

Objective To explore the effects of personalized antiplatelet therapy on the 90⁃day prognosis and safety in acute ischemic stroke(AIS). Methods Participants were recruited in 14 hospitals. The study group received personalizedantiplatelet therapy,while the control group received conventional medications based on the clinical guideline.The rate of recurrence,mRS scores and bleeding events were recorded on day 90 and then com⁃ pared between the two groups. Results 1472 patients were recruited. In the study group,the patients with clopido⁃ grel resistance accounted for 61% and those with aspirin resistance was 9.4%. The rate of recurrence was 4.1% in the study group and 4.5% in the control group(P = 0.75). The incidence of poor prognosis was 17.7% in the study group but 23.6% in the control group(P = 0.007). The rate of bleeding events was 2.4% in the study group and 2.8% in the control group(P = 0.67). Conclusions Personalized antiplatelet therapy can improve the short⁃term prognosis in patients with AIS and has no marked impacts on its safety. It provides evidence⁃based supports for clin⁃ ical precision medications.

Key words:

acute ischemic stroke, CYP2C19, 11 ? dhTxB2, precision medication, randomized controlled tria